Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The old quinidine-injection renal caution is retained for historical context. CDC documents its discontinuation and identifies IV artesunate in current severe-malaria guidance.
Before applying: Do not use this historical extract as a current malaria prescription. Follow the current CDC treatment pathway; the local summary is not a complete artesunate or follow-on regimen.
Also check: Historical IV quinidine is not current U.S. severe-malaria treatment
Rxlist source
GlobalRPh RX List - Quinidine injection
Product / population
Historical quinidine gluconate injection source; current availability and clinical role not inferred.
Renal measure
Qualitative renal-dysfunction warning; no supported numerical renal table.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
Renal dysfunction slows quinidine elimination and can produce toxicity unless the dose is reduced appropriately. The selected warning supplies no numerical renal reduction. Dialysis does not usefully remove quinidine. Kidney failure and heparin exposure can alter binding, so total serum levels may not track active unbound exposure reliably. This older injectable source is retained for historical comparison, not as current US severe-malaria treatment guidance; consult current CDC recommendations.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Historical product - not a current U.S. severe-malaria protocol. Read the CDC source comparison below before using this archival material. No current treatment regimen is inferred.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
historical source restriction
Historical IV quinidine is not current U.S. severe-malaria treatment
The old quinidine-injection renal caution is retained for historical context. CDC documents its discontinuation and identifies IV artesunate in current severe-malaria guidance.
How to use this: Do not use this historical extract as a current malaria prescription. Follow the current CDC treatment pathway; the local summary is not a complete artesunate or follow-on regimen.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Quinidine injection
Historical quinidine gluconate injection source; current availability and clinical role not inferred.
Method: Qualitative renal-dysfunction warning; no supported numerical renal table.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Historical quinidine gluconate injection source; current availability and clinical role not inferred.
Renal method: Qualitative renal-dysfunction warning; no supported numerical renal table. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Renal dysfunction slows quinidine elimination and can produce toxicity unless the dose is reduced appropriately. The selected warning supplies no numerical renal reduction. Dialysis does not usefully remove quinidine. Kidney failure and heparin exposure can alter binding, so total serum levels may not track active unbound exposure reliably. This older injectable source is retained for historical comparison, not as current US severe-malaria treatment guidance; consult current CDC recommendations.
CDC · Historical IV quinidine for severe malaria, not oral quinidine antiarrhythmic products.
Renal method: Historical product-role context; no renal regimen. Source date: March 28, 2019 (archived) Retrieved: 2026-09-07
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
CDC reported manufacturer discontinuation of IV quinidine and transition to artesunate as U.S. first-line severe-malaria treatment from April 2019. This archived announcement establishes why an old IV-quinidine monograph must not be treated as a current malaria protocol. Its historical artesunate procurement instructions are not current instructions and are not imported here.
RDM35-professional-quinidine-injection-historical-7c3dc9a490-C1 · Source locator: March 28, 2019 media statement; discontinuation and first-line transition only.
CDC · Current U.S. severe-malaria guidance contrasted with historical IV quinidine; no patient-specific antimalarial order.
Renal method: Current treatment-pathway context; no renal dose derived. Source date: August 17, 2026 Retrieved: 2026-09-07
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
CDC's August 17, 2026 guidance uses IV artesunate for severe malaria, followed by a complete oral antimalarial course when clinical and parasitemia criteria permit. Commercially available FDA-approved artesunate is obtained through distributors or another hospital; urgent procurement must not be delayed by an old quinidine reference. Follow-up includes surveillance for delayed hemolysis. This contextual summary does not reproduce a full artesunate regimen or establish a renal dose.
Additional summaries stored on this page: 0 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.